Internal Medicine

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. Neoplasms 86%
3. Therapeutics 69%
4. Survival 53%
5. Primary Myelofibrosis 51%
6. Transplants 39%
7. Liver Transplantation 37%
8. Pancreatic Neoplasms 33%
9. Colorectal Neoplasms 32%
10. Cholecystokinin Receptors 29%
11. Drug Therapy 29%
12. Eosinophils 28%
13. Endoscopy 28%
14. secretin receptor 26%
15. Safety 25%
16. Bone Marrow 25%
17. Guidelines 24%
18. Breast Neoplasms 24%
19. Adenocarcinoma 23%
20. gemcitabine 22%
21. Coccidioidomycosis 22%
22. T-Lymphocytes 22%
23. Atrial Fibrillation 22%
24. Mortality 22%
25. Confidence Intervals 22%
26. Clinical Trials 21%
27. Mutation 21%
28. Lenalidomide 21%
29. Genes 21%
30. Cell Transplantation 20%
31. Echocardiography 20%
32. Polycythemia Vera 20%
33. Population 20%
34. Colonoscopy 20%
35. Quality of Life 20%
36. Biopsy 20%
37. Transplant Recipients 19%
38. Transplantation 19%
39. Ligands 19%
40. Hemorrhage 18%
41. Cholecystokinin 18%
42. Recurrence 18%
43. Liver 18%
44. Progression-Free Survival 18%
45. Kidney 18%
46. Proteins 18%
47. Infections 18%
48. Lung 17%
49. Equipment and Supplies 17%
50. Barrett Esophagus 17%
51. Peptides 17%
52. Tissue Donors 16%
53. Pharmaceutical Preparations 16%
54. Obesity 16%
55. Physicians 16%
56. Patient Reported Outcome Measures 16%
57. Prostatic Neoplasms 16%
58. Bortezomib 16%
59. Incidence 16%
60. Cholangiocarcinoma 16%
61. INCB018424 15%
62. Plasma Cells 15%
63. Dendritic Cells 15%
64. Essential Thrombocythemia 15%
65. Irritable Bowel Syndrome 15%
66. Systematic Reviews 15%
67. G-Protein-Coupled Receptors 15%
68. Allogeneic Cells 15%
69. Hepacivirus 14%
70. Gastroesophageal Reflux 14%
71. Polyps 14%
72. Asthma 14%
73. Placebos 14%
74. Secretin 14%
75. Dexamethasone 14%
76. B-Cell Chronic Lymphocytic Leukemia 14%
77. Kidney Transplantation 14%
78. Heart 14%
79. Stem Cells 13%
80. Biliary Tract Neoplasms 13%
81. Stem Cell Transplantation 13%
82. Pancreatitis 13%
83. Randomized Controlled Trials 13%
84. Renal Cell Carcinoma 13%
85. Stomach 13%
86. Waldenstrom Macroglobulinemia 13%
87. Heart Failure 12%
88. Serum 12%
89. Pharmacokinetics 12%
90. Esophageal Neoplasms 12%
91. Technology 12%
92. Inflammation 12%
93. Neoplasm Metastasis 12%
94. B-Lymphocytes 12%
95. Costs and Cost Analysis 12%
96. Meta-Analysis 12%
97. Immunotherapy 11%
98. Graft vs Host Disease 11%
99. Fibrosis 11%